OWINGS MILLS, Md., July 15 /PRNewswire-FirstCall/ -- Medifast, Inc. (NYSE: MED) today announced that results of a recent clinical trial published in the 'Nutrition Journal' (Nutrition Journal 2010, 9:11) found that participants using the Medifast 5 & 1 Plan compared to a self-selected isocaloric food-based diet lost twice as much weight after completing an initial 16 week program.
The study tracked participants during weight-loss for 16 weeks and during weight maintenance for a period of 24 weeks. Participants were randomly assigned to either the Medifast 5 & 1 Plan or a self-selected isocaloric food-based diet.
Further results of the study showed that through 16 weeks, 93% of participants using Medifast showed significant weight-loss. The study also showed that participants on the Medifast 5 & 1 Plan demonstrated a significant increase in lean muscle mass as a percent of total weight. Participants on the Medifast 5 & 1 Plan also averaged 5 inches lost on their waistline in 16 weeks.
"This study validates the efficacy of the Medifast 5 & 1 Plan and our Medifast Meal Replacements in the clinical setting," Lisa M. Davis, Ph.D., PA-C, C.N.S., L.D.N., Vice President of Research and Development, Medifast, Inc. "Medifast continues to invest in the research and development of its products and programs to ensure that our claims to consumers are the most documented and trusted in the industry."
Medifast will continually participate in future studies, which will add even more credibility to the Medifast Brand and Programs. Medifast has been recommended by over 20,000 doctors since 1980 and customers can expect to lose up to two to five pounds per week on the Medifast 5 & 1 Plan.
"The Medifast team has worked to create an effective program that consumers can easily follow and enjoy," said Dr. Wayne Scott Andersen, Medical Director, Medifast, Inc. "We are thrilled to see that the results reflect the goals of the program and look forward to even greater success moving forward."
The Medifast 5 & 1 Plan consists of eating five Medifast Meals and one Lean & Green Meal per day. Medifast offers over 70 different menu options, with online support through the MyMedifast weight-loss community, clinical support through the Medifast Weight Control Centers, and personal support through the Take Shape For Life Health Coach Network.
MED-G
About Medifast: Medifast (NYSE: MED) is the leading easy-to-use, clinically proven, portion-controlled weight-loss program. Medifast has been recommended by over 20,000 doctors and used by over one million customers since 1980. It is committed to enriching lives by providing innovative choices for lasting health. Medifast programs have been proven effective through studies by major university teaching hospitals. The company sells its products and programs via a unique combination of four distribution channels: 1) the web and national call centers, 2) the Take Shape For Life personal coaching division, 3) Medifast Weight Control Centers, and 4) a national network of physicians. Medifast was founded in 1980 and is located in Owings Mills, Maryland. For more information, log onto http://www.choosemedifast.com.
Please Note: This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as "intend" or other similar words or the negative of such terminology. Similarly, descriptions of Medifast's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Medifast believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, Medifast's inability to attract and retain independent Associates and Members, stability in the pricing of print, TV and Direct Mail marketing initiatives affecting the cost to acquire customers, increases in competition, litigation, regulatory changes, and its planned growth into new domestic and international markets and new channels of distribution. Although Medifast's believes that the expectations, statements, and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.
SOURCE Medifast, Inc.
Advertisement
The study tracked participants during weight-loss for 16 weeks and during weight maintenance for a period of 24 weeks. Participants were randomly assigned to either the Medifast 5 & 1 Plan or a self-selected isocaloric food-based diet.
Advertisement
Further results of the study showed that through 16 weeks, 93% of participants using Medifast showed significant weight-loss. The study also showed that participants on the Medifast 5 & 1 Plan demonstrated a significant increase in lean muscle mass as a percent of total weight. Participants on the Medifast 5 & 1 Plan also averaged 5 inches lost on their waistline in 16 weeks.
"This study validates the efficacy of the Medifast 5 & 1 Plan and our Medifast Meal Replacements in the clinical setting," Lisa M. Davis, Ph.D., PA-C, C.N.S., L.D.N., Vice President of Research and Development, Medifast, Inc. "Medifast continues to invest in the research and development of its products and programs to ensure that our claims to consumers are the most documented and trusted in the industry."
Medifast will continually participate in future studies, which will add even more credibility to the Medifast Brand and Programs. Medifast has been recommended by over 20,000 doctors since 1980 and customers can expect to lose up to two to five pounds per week on the Medifast 5 & 1 Plan.
"The Medifast team has worked to create an effective program that consumers can easily follow and enjoy," said Dr. Wayne Scott Andersen, Medical Director, Medifast, Inc. "We are thrilled to see that the results reflect the goals of the program and look forward to even greater success moving forward."
The Medifast 5 & 1 Plan consists of eating five Medifast Meals and one Lean & Green Meal per day. Medifast offers over 70 different menu options, with online support through the MyMedifast weight-loss community, clinical support through the Medifast Weight Control Centers, and personal support through the Take Shape For Life Health Coach Network.
MED-G
About Medifast: Medifast (NYSE: MED) is the leading easy-to-use, clinically proven, portion-controlled weight-loss program. Medifast has been recommended by over 20,000 doctors and used by over one million customers since 1980. It is committed to enriching lives by providing innovative choices for lasting health. Medifast programs have been proven effective through studies by major university teaching hospitals. The company sells its products and programs via a unique combination of four distribution channels: 1) the web and national call centers, 2) the Take Shape For Life personal coaching division, 3) Medifast Weight Control Centers, and 4) a national network of physicians. Medifast was founded in 1980 and is located in Owings Mills, Maryland. For more information, log onto http://www.choosemedifast.com.
Please Note: This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as "intend" or other similar words or the negative of such terminology. Similarly, descriptions of Medifast's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Medifast believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, Medifast's inability to attract and retain independent Associates and Members, stability in the pricing of print, TV and Direct Mail marketing initiatives affecting the cost to acquire customers, increases in competition, litigation, regulatory changes, and its planned growth into new domestic and international markets and new channels of distribution. Although Medifast's believes that the expectations, statements, and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.
SOURCE Medifast, Inc.
